Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Patient has at least 1 year history of migraine (with or without aura)

• Females of childbearing years must use acceptable contraception throughout trial

Exclusion Criteria:

• Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)

• Patient has history or evidence of uncontrolled diabetes, or Human Immunodeficiency Virus (HIV) disease. Patient has uncontrolled cardiovascular disease

• Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)

• Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption

• Patient has a history of cancer within the last 5 years